Exelixis stock reports 10.6 percent revenue growth in Q2 2026
Published on 10/06/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exelixis stock (ISIN US30161Q1040) was last at USD 58.85 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, while the company delivered Q2 2026 revenue of USD 628.69 million, up 10.6 percent from the prior-year quarter. MarketBeat reported that the quarter also produced earnings per share of USD 0.91 against a USD 0.85 consensus estimate.
Revenue growth meets a valuation test
The Q2 figures give Exelixis a profitable operating base ahead of the next major oncology milestones. Net income reached USD 212.05 million in Q2 2026, compared with USD 210.47 million in Q1 2026, while operating profit stood at USD 248.41 million, according to the company financial data for those periods.
The earnings beat was stronger than the sales performance. Yahoo Finance lists Q2 FY26 normalized EPS at USD 0.91 versus an estimate of USD 0.87, alongside revenue of USD 628.69 million and a 33.73 percent profit margin.
Guidance carries the next risk
Exelixis lowered its fiscal 2026 revenue guidance on August 6, 2026, to USD 2.500 billion to USD 2.550 billion from USD 2.525 billion to USD 2.625 billion. Simply Wall St attributed the narrower outlook to a slower ramp for the neuroendocrine tumor indication.
The pipeline also carries a dated regulatory counter-factor. MarketScreener reported on September 10, 2026, that the FDA extended its review of zanzalintinib in combination with atezolizumab by three months. That timing shifts attention toward execution of the existing CABOMETYX franchise while investors wait for additional pipeline clarity.
Analysts see downside to targets
The consensus remains cautious despite the Q2 earnings beat. MarketBeat shows a Hold rating from 20 brokerages, with an average 12-month target of USD 50.29, a high target of USD 56.00 and a low target of USD 36.00. The average target is 14.5 percent below the USD 58.85 Nasdaq price.
EXEL stays near its yearly range
EXEL had a 52-week range of USD 33.76 to USD 61.14 as of October 5, 2026. Its market capitalization was USD 14.8 billion and trading volume was 2,580,146 shares, placing the stock 3.75 percent below its 52-week high.
Exelixis stock facts
- Company: Exelixis, Inc.
- ISIN: US30161Q1040
- Ticker: EXEL
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 58.85
- Market capitalization: USD 14.8 billion (as of October 5, 2026)
- 52-week range: USD 33.76-61.14 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
More news and analyses on Exelixis stock
